To evaluate the effect of andrographolide on monocyte chemoattractant protein-1 (MCP-1) expression at the initiation stage of atherosclerosis in rats induced by an atherogenic diet.The research was conducted on 27 rats divided into 3 groups (n=9). Group 1 was given a standard diet. Group 2 was given an atherogenic diet of vitamin D3 700.000 IU/kg on the first day followed by 5% goat fat, 2% cholesterol, 0.2% cholic acid and standard diet up to 100% for 2 days to induce atherosclerosis initiation stage. Group 3 was given an atherogenic diet and treated with andrographolide 40 mg/kg. An immunohistochemical examination was performed to determine the expression of MCP-1. Data analysis using one-way Anova followed by post hoc test.The results showed the expression of MCP-1 in group 1 was 6.61 + 1.90, in group 2 was 32.99 + 3.74 and in group 3 was 9.61 + 2.47. There was a significant difference between group 3 treated with andrographolide 40 mg/kg compared with group 2 (p<0.001). There was no significant difference between group 3 treated with andrographolide 40 mg/kg and group 1 (p>0.05).In conclusion,andrographolide may inhibit MCP-1 expression at the initiation stage of atherosclerosis in the andrographolide treated rats. Thus, andrographolide could be a potential anti-atherosclerosis drug.
Atherosclerosis is a chronic inflammatory disease that occurs in the walls of blood vessels. Various processes are involved in the pathogenesis of atherosclerosis, including inflammatory cellsinfiltration, smooth muscle cellsproliferation, increasing extracellular matrix, and formation of thrombus 1 . Inflammation has an important role and is the main mechanism underlying the pathogenesis of atherosclerosis 2 . This inflammation occurs through the interaction between monocytes and cells found in the walls of arteries such as endothelial cells and vascular smooth muscle cells 3 .
Monocytes play an essential role in theinitiation stage of atherosclerosis 4 . Inearly atherosclerotic lesions, accumulation of monocytes/macrophages can be found in the intima of blood vessels. Macrophages accumulate cholesteryl esters resulting in foam cell formation 1 .
Various existing studies show the important role of monocyte chemoattractantprotein-1 (MCP-1)in the process of recruiting monocytes/ macrophages 5 .Monocyte chemoattractantprotein-1, a C-C chemokinefamilymember, has a potent chemoattractant activity for monocytes/ macrophages 6 .This chemokine is highly expressed inthe macrophage-rich area of the atherosclerotic lesions in human as well as experimental animal models 5 . These findings suggest that monocyte chemoattractantprotein-1has an importantrole in the initiation stage of atherosclerosis.
The development of anti-atherosclerosis drugs can be done through the study on antiinflammatory drugs that act more specifically by influencing pathogenesis of atherosclerosis. One of the ingredients that has anti-inflammatory effect and potentially as anti-atherosclerosis is andrographolide, the main active ingredient contained by Andrographispaniculata.Studies that have been carried out prove that andrographolide has anti-inflammatory effect 7, 8, 9 and potential to be developed as anti-atherosclerosis 10 .
This study aimed to evaluate the andrographolide effect on MCP-1 expression at the initiation/early stage of atherosclerosis in rats induced by an atherogenic diet.
MATERIALS AND METHODS

Experimental animals
Twenty-seven male Wistar rats, 10 weeks of age (150-200 g) were obtainedfrom School of Pharmacy, University of Riau. Rats were placed in cages in a well-ventilated roomand allowed for food and water ad libitum.The room temperature was 20-26 C and room lighting was regulated light and dark for 12hours, alternately. Rat healthwas well monitoredand rat cages were cleaned everyday. Acclimatization of rats was carried out for one week before being used in this study. 
Experimental design
Rats were randomlydivided into 3 groups (n=9), Group 1 (normal control) was given a standard diet. Group 2 (atherogenic control) was given an atherogenic diet of vitamin D3 (cholecalciferol)700.000 IU/kg(Sigma, St.Louis, MO, USA) on the first day followed by 5% goat fat, 2% cholesterol, 0.2% cholic acid (Sigma, St.Louis, MO, USA) and 92.8% standard diet for 2 days to induce atherosclerosis initiation stage 11, 12 . Group 3 (treated group) was given an atherogenic diet and treated with andrographolide 40 mg/ kg (AndalasSitawaFitolab, Padang, Indonesia). Andrographolidewas given orally once a day using a gastric tube.
Evaluation of initiation stage of atherosclerosis
The initiation stage of atherosclerosis was assessed based on foam cell formation. After the treatment was completed, ether anesthesia was used to sacrifice the rats. Abdominal aortic tissues were excised rapidly and fixed in 10% neutralized formaldehyde in 0.1 M phosphate buffer. The aortic sample was embedded in paraffin. We performed a hematoxylin and eosin (H&E) staining to measure the number of foam cells in the rat abdominal aortic. Foam cells were calculated with ×400 magnification at 9 fields of view. The images were obtained using a light microscope equipped with a camera (Leica, Wetzlar, Germany) and connected to a computer monitor.
Immunohistochemical staining
MCP-1 in rat abdominal aortic were identified using MCP-1 polyclonal antibody (Bioss Antibodies Inc., Massachusetts, USA). Paraffin embedded mouse kidney with positive IHC for MCP-1 was used as positive control. Slides were observed using light microscope at ×400 magnification. Images were taken using microscope camera (Leica, Wetzlar, Germany)as many as 10 pictures each slide. MCP-1 expression in abdominal aortic was assessed by Photoshop image analysis software to calculate the percentage of area 12 . The percentage of area presented the comparison area containing MCP-1 with a whole cross section of the aorta, which is assumed to be width of expression. Two independent pathologists were invited to examine the slides.
Statistical analysis
Data are presented as mean ± SEM.Oneway analysis of variance (ANOVA) followed by Bonferroni's posthoctest was used to analyze the results. P<0.05 was considered statistically significant. 
RESULTS
Effect of atherogenic diet on foam cell formation at the initiation stage of atherosclerosis
The H&E staining showed that in Group 1 (normal control) and Group 3 (treated group) demonstrated few foam cells ( Figures 1A and 1C ), while in Group 2 (atherogenic control) showed abundance of foam cells in the aortic lesion ( Figure 1B) . These results demonstrated that the administration of an atherogenic diet induced foam cell formation in rats and andrographolide treatment reduced the accumulation of these cells in aortic lesion. Table 1 shows the number of foam cells among different experimental groups. Atherogenic diet-fed animals exhibit increased number of foam cells in the aortic lesions compared to control rats (P<0.05). Andrographolidetreatment significantly reduced the accumulation of foam cells in the aortic lesions (P<0.05).
Effect of andrographolide on MCP-1 expression
Immunohistochemical evaluation of MCP-1 in aorta section is shown in Figure 2 and Table  2 . MCP-1 expression in atherogeniccontrol group (Group 2) was markedly higher than normal control group (Group 1). However MCP-1 expression was reduced by andrographolidetreatment (Group 3).
DISCUSSION
The results of this study showed that andrographolideinhibits MCP-1 expression at the initiation stage of atherosclerosis in rats induced by an atherogenic diet.Andrographolidemay reduce foam cell formation in the early stages of atherosclerosis.
Andrographolidewas one of the main active ingredients contained byAndrographispaniculata. Recent studies were reported that andrographolide was effective in treating inflammatory diseases because it was a powerful NF-kB inhibitor 13, 14 . Andrographolide has been shown to use antiinflammatory effects in experimental models of respiratory inflammatory diseases including asthma 15 , acute lung injury (ALI) 16 , and idiopathic pulmonary fibrosis (IPF) 17 .Andrographolide has been shown to protect against stroke by inhibition ofNADPH oxidase 2 (NOX2) and inducible-nitric oxide synthase(iNOS) production via inhibition of NF-kB 18 .
In order to developeandrographolide as an effective anti-inflammatory drug,various clinical trials have been carried out, including for the treatment of sinusitis, where the drug was reportedto be effective in relievinginflammatory symptomsand well tolerated by patients 19 . Beneficial effects of A. paniculatahave been shown in a phase 2 trialof rheumatoid arthritis 20 and significantly reduced fatigue in multiple sclerosis patients 21 .
Toxicological study on andrographolide has been carried out both pre-clinical and clinical studies. In an acute toxicity study it was found that andrographolide up to 5 g/kggiven orally daily for up to 14 days in rats had no observable adverseeffect. The same results were also found in a sub-acute toxicity studywhich showed administration of oral dose of andrographolide up to 500 mg/kg given daily for up to 21 days in rats also had no observableadverse effect 22 . In a clinical trial, administration of 170 mg of A. paniculata purified extracts (about85 mg andrographolide) given orally every 12 h for 12 months was found to be well toleratedin patients with relapsingremitting multiple sclerosis. Only one patient received A. paniculata presented with a mild skin rash, which was attenuated with anti-histamine treatment 21 .
Atherosclerosis initiation stage was carried out in rats induced by atherogenic diet. We used rats in this study as experimental animal because these animals have several advantages includingbeing practical, easy to obtain and areomnivorous diet animals, more like humans. Atherosclerosis can be induced in the ratsbyadding vitamin D3 (cholecalciferol) into high-cholesteroldiet 23 . Rat model of atherosclerosis created by vitamin D3 and feedingwith an atherogenic diet is similar to the human. The composition of the atherogenic diet given in this study consisted of 5% goat fat, 2% cholesterol, 0.2% colic acid and a standard diet up to 100% 12 . Atherogenic diet was given to produce hypercholesterolemia in experimental animals. Hypercholesterolemia causes LDL to infiltrate arteries, especially at the site of hemodynamic disturbance. Oxidative and enzymatic modifications will convert LDL to oxLDL 24 . oxLDL causes endothelial dysfunction so that it will cause recruitment of monocytes into the arterial wall 25 .
Monocyte infiltration into the arterial wall plays an important role in the initiation stage and development of atherosclerotic lesion. One factor that has an important role in the recruitment of monocytes is MCP-1 26 . Varioustypes of cells presented in the walls of blood vesselssynthesize and secrete MCP-1. This chemokine has a strong chemotactic effect on monocytes/macrophages 27 . The chemotactic effect ofMCP-1 on monocytes incirculating blood is mediated by a specific highaffinity receptor CCR2 4, 5, 26 . Aiello et al demonstrated that MCP-1 can initiate atherosclerosis in mice with apolipoprotein-E deficiency 28 . Meanwhile, studies in mice with deletion of MCP-1 or CCR2 showed a decrease in monocyte accumulation in the arterial wall and prevent the formation of atherosclerotic lesions 29, 30 . These evidences prove that MCP-1 plays an important role in the atherosclerosis initiation stage and could be a potential target for atherosclerotic therapy.
The atherosclerosis initiation stage is characterized by the foam cellsformation 31 . Foam cells found at the early atherosclerotic lesion originate from monocytes in the circulation 32 .
Monocytes that have attached to vascular endothelial cells then migrate into the arterial intima layer mediated by MCP-1 24 . These monocytes will then differentiate into macrophages in response to Macrophage-Colony Stimulating Factor (M-CSF) and other stimuli 33 . Macrophages express the scavenger receptor (SR) consisting of CD36, SR-A and lectin-like oxLDL receptors-1 (LOX-1) which facilitate oxLDL particle uptake by macrophages resulting in lipid-laden foam cells 34 .
We suggest that the mechanism of inhibition of MCP-1 by andrographolide occurs through inhibition of NF-kB activation. Previous studies have shown that andrographolide has antiinflammatory effects through the inactivation of the NF-êB 13 . NF-B is a transcription factor that has an important role in regulating the genes of various cytokines and chemokines involved in the inflammatory process 35 . NF-B consists of:p105/ p50 (NF-kB1), p100/p52(NF-kB2), p65 (RelA), RelB dan c-Rel. The NF-kB pathwayis activated by the IKK (IkB kinase) complex, which consists of the regulator subunit, IKKg which is also known as the NF-kB essential modifier (NEMO), and the catalytic subunit, IKKá and IKKb. As the downstream substrate isIkbá. In normal circumstances the NF-kB p50/NF-kB p65dimer is bound to Ikbá. In response to stimuli, IKKá and IKKbwill be phosphorylated and cause Ibá phosphorylation. The phosphorylated Ikbá will degrade through the ubiquitin proteasome pathway. Ikbá degradation causes NF-kBp50/NF-kB p65 to undergo phosphorylation and translocation which eventually results in gene transcription 36 .
Inhibition of NF-kBactivity by andrographolide occurs through dephosphorylation of p65 by activating PP2A 9, 37 . Dephosphorylation of p65 by andrographolide results in decreased translocation of NF-kBinto the nucleus and reduces binding of NF-kBwith DNA 37 . Through this mechanism, andrographolide inhibits MCP-1 expression so that it will inhibit monocyte recruitment into the arterial wall.
CONCLUSION
The results of the present study suggestandrographolidehas atheroprotective effects by inhibiting MCP-1 expression and eventually suppressingmacrophage foam cell formation. Clinically, the results presented here provideinsights into the potential use of andrographolideas ananti-atherosclerotic drug.
